The aryl hydrocarbon receptor (AHR) is a ligand-activated member of the bHLH-PAS family of transcription factors. Members of this family include HIF1α, EPAS, and SIM, which are involved in hypoxia and nervous system development. Another member of this family, aryl hydrocarbon nuclear translocator (ARNT), is the dimerization partner for the AHR. The AHR is often classified as a sensor of a wide range of xenobiotics, leading to induction of xenobiotic metabolism through enhanced expression of phase I/II enzymes. The environmental contaminant 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) is a prototypic ligand for the AHR and is often used to study the effects of prolonged AHR activation. Rodent exposure to TCDD results in a plethora of toxic effects, including wasting syndrome, tumor promotion, developmental defects, and liver toxicity (reviewed in [@bib16]). The key target genes that lead to these toxic end points are largely unknown. AHR activation can occur through a growing list of chemicals that appear to be structurally diverse and include many polycyclic aromatic hydrocarbons, tryptophan metabolites, and flavones ([@bib5]). Soluble receptors such as the AHR could possibility alter transcription of target genes through several distinct mechanisms. The work of Bunger and coworkers (Bunger *et al.*, 2008) has examined whether TCDD-mediated liver toxicity can be mediated by the AHR in the absence of DNA binding.

The AHR exist in the cytoplasm as a core tetrameric complex, composed of the ligand-binding subunit, a dimer of hsp90, the X-associated protein 2 (also referred to as ARA9 or AIP), and p23 (reviewed in [@bib11]). The hsp90 and XAP2 are considered a chaperone complex that stabilizes the AHR in the cytoplasm, protecting it from proteolysis and helping the receptor maintain its ligand-binding conformation. Upon binding an agonist, a conformational change in the AHR occurs that allows access to its nuclear localization sequence, and the receptor rapidly translocates into the nucleus. In the nucleus, ARNT appears to cause displacement of hsp90, leading to the formation of the AHR/ARNT complex, which can then bind to dioxin-responsive elements (DRE) and regulate many of the receptor\'s target genes. Some of these targets include phase I drug metabolism genes such as CYP1A1, CYP1B1, and CYP1A2. The transcription of several important phase II enzymes, such as UGT1A1 and NADPH-quinone reductase, are also directly regulated by the AHR through DRE. The AHR also regulates genes with diverse functions such as p27^Kip1^, epiregulin, IGFBP-1, and Bax.

Establishment of *ahr*-null mouse models has revealed that most, if not all, of the toxic effects of TCDD are mediated through the activation of the AHR ([@bib6]). The lack of AHR expression leads to lower reproductive success, reduced life span, immunological defects, and reduced liver size ([@bib1]; [@bib13]; [@bib14]). The mechanism mediating the reduced liver size appears to be smaller hepatocytes and a portosystemic shunting of blood due to a persistent fetal vascular structure ([@bib7]). Through the use of microspheres, the portal blood flow that bypasses the *ahr*-null liver was calculated to be about 50% ([@bib7]). Using *ahr^fx/fx^* mice and *Cre*-lox technology, where the AHR was selectively disrupted in either hepatocytes or endothelial cells, revealed that the deletion of AHR expression in endothelial cells leads to a lack of developmental closure of the ductus venosus ([@bib17]). Furthermore, TCDD-mediated hepatotoxicity requires the expression of the AHR in hepatocytes.

Several research groups have performed DNA microarray studies on liver after exposure to an AHR ligand. In these experiments a large number of genes exhibit increases in messenger RNA (mRNA) levels, while interestingly an equal number of genes demonstrated a decrease in mRNA levels. These results would suggest that the AHR could both increase and decrease transcriptional levels of various genes after ligand activation. If one assumes that most of these changes in gene transcription are primary effects, then the AHR appears to be able to directly downregulate gene transcription of a subset of genes. Considering all the possible mechanisms that could be utilized by the AHR to influence gene transcription, it is a daunting task to determine which mechanism is responsible for the change in transcription of a gene that does not appear to have a functional DRE immediately upstream of its transcriptional start site.

The AHR could alter gene transcription through several different mechanisms, which are depicted in [Figure 1](#fig1){ref-type="fig"}. The first possible mechanism is through the binding of the AHR/ARNT heterocomplex to its cognate response element, and this is the mechanism that is most often studied. The second mechanism is the ability of the AHR/ARNT heterocomplex to bind to other transcription factors and modulate their ability to alter transcriptional activity. This could occur through the ability of the AHR/ARNT complex to block recruitment of a transcription factor to an enhancer/promoter region or through binding to a transcription factor at the promoter. A third distinct mechanism that has been considered is the possibility that the AHR in the cytoplasm is capable of binding to other proteins and modulating their activity, such as evidence for activation of c-src upon dissociation from the AHR cytoplasmic complex after ligand binding ([@bib10]). Similar studies with nuclear hormone receptors suggest that such mechanisms need not be mutually exclusive, thus further increasing the level of complexity associated with AHR signaling and toxicity. The Bradfield laboratory has decided to tackle this issue through the development of genetically altered mouse lines that express mutant forms of the AHR with distinct characteristics. The first line was made using homologous recombination to introduce a mutation in the nuclear localization sequence, which is also part of the DNA-binding domain ([@bib4]). These mice, designated as *Ahr^nls/nls^*, express an AHR that fails to translocate into the nucleus, bind to its cognate response element, or induce cytochrome P-450 enzymatic activity. However, this mutant retained its ability to bind to hsp90, XAP2, and ligand. Treatment of *Ahr^nls/nls^* mice with TCDD revealed that the mutant AHR mice did not exhibit any change in liver or thymus weight, which is seen in *Ahr^+/+^* mice. This mouse model would indicate that TCDD-mediated hepatotoxicity requires the AHR to be present in the nucleus.

![Five possible distinct mechanisms of AHR function that could lead to altered gene transcription. (1) Cytoplasmic protein-binding events; (2) AHR sequesters and blocks another transcription factor\'s ability to bind to its cognate response element; (3) AHR binds as a monomer to a transcription factor bound to its cognate response element; (4) AHR/ARNT binds to a transcription factor bound to its cognate response element; and (5) AHR/ARNT bind to a DRE.](toxscikfn220f01_ht){#fig1}

Bradfield *et al.* developed a second mouse model that expresses an AHR mutant designated *Ahr^dbd/dbd^*. The AHR in this mouse model is capable of translocating into the nucleus and heterodimerizing with ARNT, yet is incapable of binding a DRE ([@bib3]). The actual mutation introduced into the *Ahr*-coding sequence was the addition of a glycine and serine between the arginine-39 and aspartate-40 residues. Expression of the AHR-dbd failed to enhance DRE-driven transcriptional activity. While this mutant AHR is capable of binding to hsp90 and ligand, its expression in cells leads to a constitutive localization in the nucleus. This would suggest that changes in the structure of the AHR near the NLS apparently leads to recognition by the nuclear translocation machinery. Despite nuclear localization and its ability to heterodimerize with ARNT, the TCDD-AHR-dbd complex failed to mediate cleft palate, hydronephrosis, thymic involution, or hepatomegaly. Several investigators have hypothesized that part of the toxicity of TCDD may be through the ability of an highly activated AHR to sequester ARNT away from its other partners (e.g., HIF1α). Results obtained with the AHR-dbd--expressing mice would support the concept that sequestration of ARNT is not a major factor in the toxicities tested. Thus, both the *Ahr^nls/nls^* and *Ahr^dbd/dbd^* mouse model firmly support the concept that overt toxicities mediated by TCDD exposure requires DRE-driven transcriptional activity.

The development of a mouse that expresses a DNA-binding mutant AHR goes well beyond its use in TCDD-mediated toxicity studies. This mouse model may be particularly important in determining whether the AHR/ARNT heterodimer in the nucleus is capable of altering gene transcription through protein-protein interacting events, leading to nontoxic phenotypic end points. This nonclassical mechanism of transcription factor/receptor function has been demonstrated with nuclear receptors (e.g., ER, AR) that can modulate transcription through mechanisms other than binding to their cognate DNA response element. This type of activity in the nucleus can be mediated by several distinct mechanisms. However, there appears to be two main mechanisms, with the first being the binding of one transcription factor (TF) to another, leading to inhibition of the activity of one of the TFs; this can be termed the "sequestration" mechanism. The second mechanism involves tethering of one TF to another that is bound to its cognate DNA response element in a specific enhancer/promoter region; this can be termed "transrepression." One of the best illustrations of promoter tethering is the transrepression of certain NF-κB--regulated genes by the glucocorticoid receptor (GR) ([@bib8]). To further explore the tethering activity of the GR, a point mutant in the GR-A458T was knocked into the GR gene using the Cre/loxP system in mice ([@bib12]). This GR mutant fails to dimerize in the presence of dexamethasone and thus fails to recognize glucocorticoid receptor response element. Interestingly, these mice survive and are fertile, in contrast to GR-null mice that die shortly after birth. The transrepression response was demonstrated to occur with several genes and known to be repressed after dexamethasone treatment, in these mutant GR mice. Another example is the ability of the estrogen receptor to mediate transrepression of the RelA ([@bib15]). The ER can also tether to the AhR/ARNT heterodimer at the CYP1A1 promoter ([@bib2]). Conversely, recruitment of the AhR/ARNT heterodimer to ERα in MCF-7 on the pS2 promoter results in a repression of pS2 mRNA levels in the presence of estrogen and the AHR ligand 3-MC ([@bib9]). How widespread the level of gene modulation by the AhR through non-DRE--mediated mechanisms has not been explored. In addition, it is not clear whether the AhR alone can modulate transcription as described for the monomeric GR or if the AhR must heterodimerize with ARNT to exhibit this type of activity. Future studies utilizing the mutant AHR mouse models developed by the Bradfield laboratory should shed light on the multiple mechanisms of gene regulation mediated by the AHR.
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